Selinexor Produces Responses in HMA-Refractory MDS, Oligoblastic AML
Selinexor yields responses in patients with MDS or oligoblastic AML refractory to hypomethylating agents, with manageable adverse events.
Lauren Dembeck, PhD
Contributing Writer https://www.cancertherapyadvisor.com
Lauren Dembeck is a freelance science and medical writer and a contributing author for the Haymarket Medical Network. She holds a BS in biology and a BA in foreign languages from West Virginia University and a PhD in genetics from North Carolina State University. Prior to freelance writing, Lauren was a postdoctoral researcher at the Okinawa Institute of Science and Technology in Japan, where she studied developmental neurobiology. You can find more of her writing at https://laurendembeck.com/
